Stocktoria
Neurogene Inc. NGNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-07
Neurogene Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $925,000 | $0 | — | — |
| R&D expense | $75.0M | $60.9M | $44.4M | $47.5M | $39.2M |
| Operating income | -$103.3M | -$82.6M | -$55.6M | -$56.5M | -$60.7M |
| Interest expense | — | — | $12,000 | $2,000 | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$55.2M | -$60.7M |
| EPS (diluted) | $-4.24 | $-4.28 | — | $-1.04 | $-1.10 |
| Operating cash flow | -$77.2M | -$70.6M | -$51.4M | -$52.8M | -$47.6M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$55.1M | -$50.8M |
| Cash & equivalents | $103.8M | $136.6M | $148.2M | $82.0M | $142.5M |
| Total assets | $288.6M | $335.7M | $222.6M | $109.3M | $163.3M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $10.6M | $20.4M |
| Shareholders' equity | $264.9M | $310.4M | $186.0M | -$145.7M | -$91.9M |
Source: SEC EDGAR filings · CIK 0001404644 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.